专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016172124A1 SELECT SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTIVE OF RESPONSE TO GLATIRAMER ACETATE 审中-公开
标题翻译：选择单核苷酸多态性对乙酰胆碱反应的预测
公开(公告)号：WO2016172124A1
公开(公告)日：2016-10-27
申请号：PCT/US2016/028316
申请日：2016-04-19
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , GROSSMAN, Iris , HAYDEN, Michael , ROSS, Colin, James Douglas , LAIFENFELD, Daphna , DAVIS, Matthew
发明人： GROSSMAN, Iris , HAYDEN, Michael , ROSS, Colin, James Douglas , LAIFENFELD, Daphna , DAVIS, Matthew
IPC分类号： A61K38/02 , C12Q1/68
CPC分类号： C12Q1/6883 , A61K9/0019 , A61K38/02 , A61K45/06 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent, with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: rs1894408, kgp7747883, kgp6599438, rs10162089, rs16886004, kgp8110667, kgp8817856, kgp24415534, kgp6214351 and rs759458, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of kgp8110667, rs10162089, rs759458 and kgp6214351, or one or more G alleles at the location of kgp24415534, kgp6599438, kgp7747883, kgp8817856, rs16886004 and rs1894408; and iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
摘要翻译：本发明提供了一种用多种硬化症或单一临床攻击治疗患有多发性硬化的人类受试者的方法，所述多发性硬化症包括含有醋酸格拉默和药学上可接受的载体的药物组合物，包括以下步骤：（i）确定对应于选自以下的一个或多个单核苷酸多态性（SNP）的位置的对象：rs1894408，kgp7747883，kgp6599438，rs10162089，rs16886004，kgp8110667，kgp8817856，kgp24415534，kgp6214351和rs759458，（ii）鉴定该受试者作为乙酸格拉默的预测应答者，如果受试者的基因型在kgp8110667，rs10162089，rs759458和kgp6214351的位置包含一个或多个A等位基因，或位于kgp24415534，kgp6599438，kgp7747883，kgp8817856的一个或多个G等位基因，rs16886004和rs1894408; 以及iii）仅当所述受试者被鉴定为乙酸格拉默的预测应答者时，向受试者施用包含乙酸格拉默和药学上可接受的载体的药物组合物。

2. 发明申请

WO2015061367A1 GENETIC MARKERS PREDICTIVE OF RESPONSE TO GLATIRAMER ACETATE 审中-公开
标题翻译：遗传标记对乙酰胆碱酯酶的反应
公开(公告)号：WO2015061367A1
公开(公告)日：2015-04-30
申请号：PCT/US2014/061647
申请日：2014-10-21
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , TCHELET, Amir , HAYDEN, Michael , HAYARDENY, Liat , ROSS, Colin, James Douglas , GROSSMAN, Iris , LADKANI, David
发明人： TCHELET, Amir , HAYDEN, Michael , HAYARDENY, Liat , ROSS, Colin, James Douglas , GROSSMAN, Iris , LADKANI, David
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K38/02 , A61K38/16 , C12Q2600/106 , C12Q2600/156
摘要： The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype corresponding to the nucleotide polymorphisms consisting of: Group 1, of the subject at a location location of one or more single (SNPs) selected from the group.
摘要翻译：本发明提供了一种治疗患有多发性硬化的人类受试者或与多发性硬化一致的单一临床攻击的方法，所述药物组合物包含乙酸格拉默和药学上可接受的载体，包括以下步骤：（i）确定对应于所述核苷酸多态性由选自组中的一个或多个单个（SNP）的位置位置处的受试者的组1组成。

3. 发明公开

EP3060681A1 GENETIC MARKERS PREDICTIVE OF RESPONSE TO GLATIRAMER ACETATE 审中-公开
标题翻译： GENETISCHE MARKER ALSPRÄDIKTORENDER REAKING AUF GLATIRAMERACETAT
公开(公告)号：EP3060681A1
公开(公告)日：2016-08-31
申请号：EP14855499.1
申请日：2014-10-21
申请人： Teva Pharmaceutical Industries Ltd.
发明人： TCHELET, Amir , HAYDEN, Michael , HAYARDENY, Liat , ROSS, Colin, James Douglas , GROSSMAN, Iris , LADKANI, David
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K38/02 , A61K38/16 , C12Q2600/106 , C12Q2600/156
摘要： The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of Group 2, one or more C alleles at the location of Group 3, one or more G alleles at the location of Group 4, or one or more T alleles at the location of kgp18432055, kgp279772, kgp3991733 or kgp7242489; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
摘要翻译：本发明提供了一种治疗患有多发性硬化的人类受试者或与多发性硬化一致的单一临床攻击的方法，所述药物组合物包含乙酸格拉默和药学上可接受的载体的药物组合物，包括以下步骤：（i）确定受试者在对应于选自以下的一个或多个单核苷酸多态性（SNP）的位置的位置：组1，（ii）如果受试者的基因型含有一个或多个，则将该受试者鉴定为乙酸格拉默的预测应答者在组2的位置，在组3的位置上的一个或多个C等位基因，在组4的位置的一个或多个G等位基因，或位于kgp18432055，kgp279772，kgp3991733或 kgp7242489; 和（iii）仅当受试者被鉴定为乙酸格拉默的预测应答者时，向受试者施用包含乙酸格拉默和药学上可接受的载体的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式